JUNS
Jupiter Neurosciences, Inc.Healthcare·Biotechnology
--
$0M market cap
Revenue
$0.0M
Free Cash Flow
$-3.8M
Rev Growth
+0.0%
FCF Margin
-9395.1%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 tha
2-Year Price History
$0.24-96.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -2.0 | -2.0 | -2.1 | -1.4 | -1.4 | -0.0 | 2.4 | 4.8 | 35.3 | -162.5% | -16.6x | -- |
| Act | 2025-Q4 | 0.0 | -2.5 | -2.8 | -2.6 | -2.4 | -2.4 | -0.0 | 3.8 | 5.3 | 34.5 | -211.2% | -706.4x | -- |
Valuation & Metrics
Market Stats
Price--
Market Cap$0M
Enterprise Value$2M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)-9395.1%
FCF Yield0.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-4.6M
Free Cash Flow$-3.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin-11065.0%
Net Margin-11464.1%
FCF Margin-9395.1%
CapEx % of Revenue0.0%
SBC % of Revenue-4834.0%
ROIC-186.8%
WC Change % Rev29.0%
Interest Coverage-38.9x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.1M
Days to Cover1.0
Change (vs Prior)-9.8%
Need at least 2 settlement dates for chart
Employees
Headcount4
Revenue / Employee$10,112
Gross Profit / Employee$9,022
Cash Runway
7.5months
CRITICAL
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
4.5%(+2.7% YoY)
5 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.6%(+2.5% YoY)
4 filers
Vanguard, iShares, SPDR
Market makers
0.0%(-0.4% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| VESTOR CAPITAL, LLC | $365K | $1.07 | +$365K | +$365K | +1.0% | $1.38B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $135K | $0.38 | +$135K | +$135K | — | $4.04T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $80K | $1.14 | +$30K | +$80K | +2.3% | $1.61T |
| Yorkville Advisors Global, LP | $49K | $1.02 | −$1K | +$49K | -65.5% | $147M |
| CITADEL ADVISORS LLC | $38K | $0.38 | +$38K | +$38K | -0.4% | $138.22B |
| VANGUARD FIDUCIARY TRUST COPassive | $33K | $0.38 | +$33K | +$33K | — | $395.83B |
| NORTHERN TRUST CORPPassive | $10K | $1.74 | +$0 | +$10K | -0.2% | $755.34B |
| Virtu Financial LLCMM | $5K | $0.38 | +$5K | +$5K | -2.0% | $2.41B |
| UBS Group AG | $1K | $0.61 | −$0 | −$50K | -0.3% | $562.11B |
| MidFirst Bank | $0 | $1.02 | +$0 | +$0 | +2.5% | $1.21B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-6.25%
avg per quarter
Holders (ex-self)
-6.24%
excl. this stock
Buyers (this Q)
+0.85%
5 buyers · $0.00B in
Sellers (this Q)
-61.40%
2 sellers · $0.00B out
alpha coverage: 76% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+14.6%
how holders react when this stock falls
On quiet Qs
-18.4%
−10% to +10% baseline
On rallies (+10%+)
-74.3%
how they react when this stock rises
Holders' portfolio flow this Q
+153.2%
inflows — adds are organic
Sellers' portfolio flow this Q
+27.3%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-36.1%
Holder mid (any stock)
-18.4%
Holder rally (any stock)
-7.0%
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 93.1%
VESTOR CAPITAL, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
GEODE CAPITAL MANAGEMENT, LLC--
Yorkville Advisors Global, LP--
CITADEL ADVISORS LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
VESTOR CAPITAL, LLC971KYorkville Advisors Global, LP129KUBS Group AG4KCITIGROUP INC—CITADEL ADVISORS LLC102KAllen Capital Group, LLC—XTX Topco Ltd—TWO SIGMA INVESTMENTS, LP—HRT FINANCIAL LP—Qube Research & Technologies Ltd—
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$3K
3 txns · 1 insider · 2,550 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$12K
3 txns · 1 insider · 11,416 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-07-01 | BUY | ROSEN CHRISTER | director, 10 percent owner, officer: CEO and Chairman | 3,600 | $1.02 | $4K | $11.29M |
| 2025-07-01 | BUY | Silva Alison D. | director, officer: Pres + Chief Business Officer | 750 | $1.03 | $772 | $116K |
| 2025-06-30 | BUY | ROSEN CHRISTER | director, 10 percent owner, officer: CEO and Chairman | 7,650 | $1.02 | $8K | $11.31M |
| 2025-06-30 | BUY | Silva Alison D. | director, officer: Pres + Chief Business Officer | 950 | $1.03 | $978 | $115K |
| 2025-06-27 | BUY | ROSEN CHRISTER | director, 10 percent owner, officer: CEO and Chairman | 166 | $1.06 | $176 | $11.73M |
| 2025-06-27 | BUY | Silva Alison D. | director, officer: Pres + Chief Business Officer | 850 | $1.03 | $877 | $115K |
Order Flow (FINRA, ~3w lag)
69.5%retail+7.6pp
2.6%dark-0.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Jupiter Neurosciences: A High-Burn Clinical Entity Surviving on Death-Spiral Financing
Overall Risk
9/10
Fraud
4/10
Dilution
10/10
Insolvency
9/10
Earnings Overstated
3/10
Hidden Liabilities
6/10
Legal
4/10
Audit Warnings
9/10
Hidden Upside
2/10
Contextually Acceptable
3/10